Navigation Links
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Date:8/3/2009

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).

As of the time of data analysis in April 2009, 10 of the 16 studied patients were alive without evidence of disease progression, of whom eight continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8 years, respectively, and were without evidence of disease progression. Nine of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Six of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased.

Prolonged treatment with Stimuvax was well-tolerated in this trial. The most common treatment-related adverse events were injection-site reactions, which tended to diminish after the first year of treatment. There was no evidence of autoimmune reactions with prolonged use.

The Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was conducted by Oncothyreon, with patient enrollment concluding in 2003. Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt,
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon announces closing of $11.1 million registered direct financing
5. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Oncothyreon reports first quarter 2009 financial results
9. Oncothyreon regains compliance with NASDAQ listing requirements
10. Oncothyreon to present at Invest Northwest 2009
11. Oncothyreon reports full year and fourth quarter 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Can economic incentives such ... motivate members of the public to increase their donations ... Johns Hopkins Carey Business School Assistant Professor Mario ... to a large body of recent research that supports ... 24, 2013, issue of Science that the World Health ...
(Date:5/23/2013)... May 23, 2013 The maker community ... types of inventions. They focus on learning practical skills ... community gravitate toward bringing their ideas to life via ... Movement, works on making projects using biology. Glowing Plant ... plants to make them glow with bioluminescence genes, and ...
(Date:5/23/2013)... EXTON, Pa. , May 23, 2013 /PRNewswire/ ... leading research and advisory firms for specialized biopharmaceutical ... gastroenterologists, hepatologists, and infectious disease specialists reported that ... warehousing patients (e.g., intentionally delaying treatment) in anticipation ... physicians than six months ago, when only 6 ...
(Date:5/23/2013)... 2013 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... host a teleconference to discuss its First Quarter 2013 ... teleconference information is provided below: Date: Thursday, ... (EDT) Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ... VS22823 For those unable to participate in ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... Zero Zone, Inc., of North Prairie, Wisconsin, has signed ... software. The new software is fully integrated with ... including IFS' supply chain management and financial applications, which ... and freezer display cases used primarily by grocery, convenience, ...
... the hyperboleers, there is a B-movie style, winner-take-all battle of ... Old Economy. In round one, the New Economy stomped around ... the death of the Old Economy. In round two, the ... of the ring, crushing many innocent and not-so-innocent bystanders in ...
... Automating Peripherals, Inc., announced today the official name ... is a provider of time and attendance, ... and access control software for healthcare organizations. ... while serving the healthcare industry as Automating Peripherals, ...
Cached Biology Technology:Zero Zone Adds Sales and Marketing Automation Tools 2The Old Economy Vs. the New Economy 2The Old Economy Vs. the New Economy 3
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
(Date:5/22/2013)... Legionella pneumophila bacteria is responsible for legionellosis, an ... to infect us, this pathogen has developed a complex ... in our cells, thus avoiding these acting against the ... research centre, CIC bioGUNE, in which teams from the ... the National Supercomputation Centre in Barcelona (BSC) have also ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Mechanism discovered which aids Legionella to camouflage itself in the organism 2
... antibody targeting a well known cell surface protein inhibited ... of the disease that did not respond to hormone ... UCLA Department of Urology and UCLA,s Jonsson Comprehensive Cancer ... N-cadherin, is up regulated or turned on in prostate ...
... This release is available in French . , Frank ... table would make people more aggressive, not less. After all, dont ... a game in hopes of pumping them up? And what about ... who dares take their meat away from them? Wouldnt that go ...
... Miss. A summit that,s both scientific conference and ... front lines of fighting obesity and related metabolic diseases ... sponsored by the University of Mississippi Medical Center and ... the Jackson Convention Complex. Obesity and related ...
Cached Biology News:UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Caveman behavioral traits might kick in at Thanksgiving table before eating 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 2Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 3Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 4Global Obesity Summit 2010 in Jackson addresses growing epidemic at ground zero 5
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: